$Precigen(PGEN)$ It's been almost a year since I last posted about this ticker back then in August 2025; https://tigr.link/s/30HSadE. Back then, stock was trading at about $2.60. 11 months have past. We see that PGEN has shifted significantly from a pre-commercial speculative biotech company to a validated commercial stage one. Primary driver for this important milestone is the launch of PAPZIMEOS, its gene therapy for recurrent respiratory papillomatosis in adults. In 2026Q1, this has generated $21.6M in net product revenue ( massive jump from $3.4M in 2025Q4 ). Total revenue has reached $23.25M, beating expectations of $20M. With their optimistic target to achieve cash flow break even by end of this year, 2026Q1 operating loss has narrowed down
$Singtel(Z74.SI)$ I last talk about this counter was back in 2023, it’s been months and market conditions + SingTel prices have changed however my position remains the same. Last closing price on 12 July was $2.95. The last time we saw this price was in 2020 March pandemic. SingTel prices was on the downtrend. $2.95 wasn’t even support price because $2.95 was not only broken easily but price dive further down the months. Right now, $2.95 became the resistance price instead, having tested on 11 & 12 July. Since Jun 2024 with SingTel joint venture into developing next gen data centre in Msia, the upward trend got steeper. With the sell down of Airtel , capital recycling to unlock value from its assets and partnering with lend